Figure 5 | Scientific Reports

Figure 5

From: Oxytetracycline have the therapeutic efficiency in CD133+ HCC population through suppression CD133 expression by decreasing of protein stability of CD133

Figure 5

Decrease of tumor size and CD133+ population mouse model. (A) Tumor size of indicated groups. When the tumor volume was reached 150–200 mm3, mice were randomized to 3 groups (Saline, Sorafenib, Oxytetracycline) were injected for 5 days. The tumor volume in the indicated mouse groups was examined every 2 days for evaluating the compounds effects. (B) Immunohistochemistry of CD133 in Huh7.5 tumor tissues of indicated groups in xenograft mice. Data are shown as the mean and standard deviation (SD) of five animals in each group. *p < 0.05, **p < 0.005.

Back to article page